Sign In
Buy FOLD
$9.42
-0.0600 (-0.633%)
At Close: Nov 17, 2025
Amicus Therapeutics: Moving Towards Consistent Profitability
04:56pm, Tuesday, 11'th Nov 2025
Amicus Therapeutics (FOLD) is progressing toward profitability, driven by strong Q3 results and expanding global approvals for its rare disease therapies. FOLD's revenue grew 19.5% year-over-year, wit
Amicus Therapeutics, Inc. (FOLD) Presents at UBS Global Healthcare Conference 2025 Transcript
06:11pm, Monday, 10'th Nov 2025
Amicus Therapeutics, Inc. ( FOLD ) UBS Global Healthcare Conference 2025 November 10, 2025 2:45 PM EST Company Participants Jeffrey Castelli - Chief Development Officer Presentation Unknown Analyst Gr
Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade
10:56am, Monday, 10'th Nov 2025
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
11:41am, Friday, 07'th Nov 2025
EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
11:11am, Wednesday, 05'th Nov 2025
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics
10:31am, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare w
Amicus Therapeutics, Inc. (FOLD) Q3 2025 Earnings Call Transcript
03:56pm, Tuesday, 04'th Nov 2025
Amicus Therapeutics, Inc. ( FOLD ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - CEO, President & Di
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
09:37am, Tuesday, 04'th Nov 2025
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.1 per share a year ago.
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
07:00am, Tuesday, 04'th Nov 2025
Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
07:00am, Friday, 31'st Oct 2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
07:00am, Thursday, 23'rd Oct 2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025,
Amicus Therapeutics: Turning The Corner To Profitability With 2 Developing Therapies
08:47pm, Wednesday, 22'nd Oct 2025
Amicus Therapeutics remains a Buy, supported by strong momentum in Galafold and Pombiliti/Opfolda, both with blockbuster potential. FOLD's Galafold leads in Fabry disease as the first oral precision m
All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 07'th Oct 2025
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
10:26am, Monday, 06'th Oct 2025
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
10:41am, Thursday, 02'nd Oct 2025
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
